OrthoPediatrics reports record 2025 revenue $236.3M (+15% YoY); Q4 first positive free cash flow $9.8M

ORTHOPEDIATRICS CORP

2025-FY EPS reported -$1.69 revenue$236,348,000

Record FY2025 revenue $236.3M, up 15% from $204.7M in 2024.
Q4 2025 revenue $61.6M (+17% YoY); net loss per share $0.43 vs $0.69.
Adjusted EBITDA FY2025 $14.8M vs $8.5M; Q4 adjusted EBITDA $4.8M vs $3.0M.
Generated $9.8M free cash flow in Q4, first positive FCF quarter; cash $62.9M.
FY2026 guidance: revenue $262-266M (11-13% growth), adjusted EBITDA ~$25M, breakeven cash flow.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.